Biblio Discovery — Demo Discovery Service

5 results for "Quanwei Yu"

Showing 1–5 · 0.53 seconds · RSS

  1. Journal Article

    Reconstruction of de novo verazine biosynthesis in Saccharomyces cerevisiae and computational analysis of cholesterol-binding geometry for 22R hydroxylation by VcCYP90B27 to dissect the cyclopamine biosynthetic pathway

    Chang Li; Quanwei Yu; Fang Yue et al.

    Engineering in Life Sciences, Vol. 26 No. 8 · 2026 · English · DOAJ Scopus

    Cyclopamine, a typical isosteroidal alkaloid identified as a hedgehog pathway inhibitor, serves as a crucial molecular scaffold for the semi-synthesis of drugs treating nevoid basal cell carcinoma. Verazine is a key intermediate in the biosynthetic pathway of cyclopamine. In this study, we…

  2. Journal Article

    SARS-CoV-2 SUD2 and Nsp5 Conspire to Boost Apoptosis of Respiratory Epithelial Cells via an Augmented Interaction with the G-Quadruplex of BclII

    Ying Li; Quanwei Yu; Ridong Huang et al.

    mBio, Vol. 14 No. 2 · 2023 · English · DOAJ Scopus

    ABSTRACT The molecular mechanisms underlying how SUD2 recruits other proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to exert its G-quadruplex (G4)-dependent pathogenic function is unknown. Herein, Nsp5 was singled out as a binding partner of the SUD2-N+M domains (SUD2core)…

  3. Journal Article

    SARS-CoV-2 SUD2core promotes neutrophil-mediated inflammation by disabling HEBP2-mediated restraint on granule exocytosis

    Ying Li; Songjun Shao; Qian Lei et al.

    Cell Reports, Vol. 45 No. 9 · 2026 · English · DOAJ Scopus

    Summary: The molecular basis of neutrophil-driven immunopathology in severe coronavirus disease 2019 (COVID-19) remains poorly defined. Here, we identify the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) SARS-unique domain (SUD)2core domain as a direct binding partner of the…

  4. Journal Article

    A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations

    Hui Deng; Qian Lei; Chengdi Wang et al.

    Nature Communications, Vol. 13 No. 1 · 2022 · English · DOAJ Scopus

    The presence of activating epidermal growth factor receptor (EGFR) mutations in patients with lung cancer correlates to improved response to EGFR-tyrosine kinase inhibitors. Here, the authors present a fluorescence-activated cell sorting assay to identify EGFR mutations with functional activity in…